title: New agents in medical oncology and the risk of venous thromboembolism.
abstract: Over the past several years the medical approach to cancer patients has made important steps forward both in the field of novel, selective, antiproliferative agents and more effective supportive therapies. A greater understanding of the molecular pathways regulating cell proliferation and metastasis has led to the identification of a range of targets specifically inhibited by these new drugs. The clinical development of these compounds (the so called "targeted therapies") has shown distinctive adverse effects with respect to standard chemotherapeutic agents but the potential increasing risk of venous thromboembolism remains unvaried. In fact, the incidence of this potentially life-threatening complication in patients receiving standard chemotherapy ranges from about 11% to 20% and even more depending on the type of drug administered and on the possible association with other anti-neoplastic and supportive therapies. In this paper we reviewed all the available evidences concerning the increasing risk of venous thromboembolism in cancer patients during treatment with new agents currently used in medical oncology together with data concerning the clinical value of a concomitant prophylactic anticoagulation. At present, additional information concerning safety in terms of thromboembolic risk of novel biological and molecular therapies should be collected from specifically designed original basic science studies and clinical trials in order to optimize their use in current oncology practice.
authors.affiliation: 1st Department of Internal Medicine, Thromboembolic Disease Unit, Fondazione IRCCS San Matteo and University, Pavia, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Manzoni
authors.forename: K
authors.initials: K
authors.lastname: Bencardino
authors.forename: F
authors.initials: F
authors.lastname: Piovella
authors.forename: S
authors.initials: S
authors.lastname: Chatzileontiadou
authors.forename: S
authors.initials: S
authors.lastname: Delfanti
authors.forename: A
authors.initials: A
authors.lastname: Riccardi
authors.forename: M
authors.initials: M
authors.lastname: Danova
authors.forename: G R
authors.initials: GR
authors.lastname: Corazza
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D012306:Risk; D013923:Thromboembolism / Q000453:epidemiology*; D020246:Venous Thrombosis / Q000453:epidemiology*
chemical_list: D000970:Antineoplastic Agents